Jeroen Janssen

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka et al. · Blood · 2021 · 101 citations

Medicine, Hematology, Oncology +17

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Uma Borate, Jordi Esteve, Kimmo Porkka et al. · Blood · 2019 · 85 citations

Medicine, Hematology, Pharmacology +17

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Andrew M. Brunner, Jordi Esteve, Kimmo Porkka et al. · Blood · 2020 · 70 citations

Medicine, Oncology, Pharmacology +16

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS

GJ Ossenkoppele, Georg Stuessi, Yvette van Norden et al. · Leukemia · 2020 · 23 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +7

AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study

Andrew M. Brunner, Uma Borate, Jordi Esteve et al. · Clinical Lymphoma Myeloma & Leukemia · 2020 · 18 citations

Medicine, Hematology, Oncology +17